Quantum Cyber vs Exicure
QUCY and XCUR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How QUCY and XCUR compare
Exicure scores higher on the StockData Score (4 against 3 for Quantum Cyber), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | QUCY | XCUR |
|---|---|---|
| Size and price | ||
| Market cap | – | $7.0M |
| Share price | $0.630 | $1.07 |
| Change, 1 year | −53.7% | −70.7% |
| Change, 5 years | −93.6% | −98.6% |
| Beta (5Y) | – | −0.97 |
| Employees | 3 | 8 |
| StockData Score | ||
| Total score | 3 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 7.2× |
| Growth | ||
| Revenue growth (TTM) | −39.9% | – |
| Revenue growth, 5Y average | 1.7% | – |
| Profitability | ||
| Gross margin | 72.6% | – |
| Operating margin | −3005% | – |
| Net margin | −3018% | – |
| FCF margin | −2045% | – |
| Return on equity | −141% (better) | −168% |
| Return on invested capital | −324% (better) | −4377% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −43.2× | – |
| Current ratio | 5.56 (better) | 0.56 |
| Altman Z-score | – | −27.36 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 2.4% | 2.1% |
| Held by insiders | – | 92.6% |
| Insider net buying, 12 months | $0 (better) | −$11.6M |
| Short interest, % of float | – | 10.8% |
Go deeper
- QUCY stock overview
- QUCY income statement
- QUCY valuation and score
- XCUR stock overview
- XCUR income statement
- XCUR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.